Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Scott Patterson

Showing results (21-30 of 61) with videos related to

Pageof 7
Sort By:
The Pediatric Infectious Disease Journal|March 30, 2013
Immunogenicity and safety of a 13-valent pneumococcal conjugate vaccine in healthy infants in JapanTakehiro Togashi, Masako Yamaji, Allison Thompson, et al.
Journal of Immunology (Baltimore, Md. : 1950)|August 21, 2008
Human invariant NKT cells display alloreactivity instructed by invariant TCR-CD1d interaction and killer Ig receptorsScott Patterson, Aristeidis Chaidos, David C A Neville, et al.
Vaccine|December 18, 2017
Serotype-specific immune responses to pneumococcal conjugate vaccine among children are significantly correlated by individual: Analysis of randomized controlled trial dataMarc Lipsitch, Lucy M Li, Scott Patterson, et al.
Proceedings of the National Academy of Sciences of the United States of America|June 21, 2006
Phosphoproteomic analysis of Her2/neu signaling and inhibitionRon Bose, Henrik Molina, A Scott Patterson, et al.
Vaccine|July 17, 2016
Modeling pneumococcal nasopharyngeal acquisition as a function of anticapsular serum antibody concentrations after pneumococcal conjugate vaccine administrationRon Dagan, Christine Juergens, James Trammel, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|June 28, 2013
Comparative immunogenicity and efficacy of 13-valent and 7-valent pneumococcal conjugate vaccines in reducing nasopharyngeal colonization: a randomized double-blind trialRon Dagan, Scott Patterson, Christine Juergens, et al.
Vaccine|January 15, 2017
PCV13-vaccinated children still carrying PCV13 additional serotypes show similar carriage density to a control group of PCV7-vaccinated childrenRon Dagan, Christine Juergens, James Trammel, et al.
Human Vaccines & Immunotherapeutics|March 16, 2018
Late onset of injection site reactions after vaccination with the 13-valent pneumococcal conjugate vaccine in adult study populationsChristine Juergens, James Trammel, Yasuko Shoji, et al.
Clinical and Vaccine Immunology : CVI|July 4, 2014
Post hoc analysis of a randomized double-blind trial of the correlation of functional and binding antibody responses elicited by 13-valent and 7-valent pneumococcal conjugate vaccines and association with nasopharyngeal colonizationChristine Juergens, Scott Patterson, James Trammel, et al.
Journal of Immunology (Baltimore, Md. : 1950)|October 8, 2005
Human invariant NKT cells are required for effective in vitro alloresponsesScott Patterson, Ioannis Kotsianidis, Antonio Almeida, et al.
Pageof 7

Showing results (21-30 of 61) with videos related to

Sort By:
Pageof 7
The Pediatric Infectious Disease Journal|March 30, 2013
Immunogenicity and safety of a 13-valent pneumococcal conjugate vaccine in healthy infants in JapanTakehiro Togashi, Masako Yamaji, Allison Thompson, et al.
Journal of Immunology (Baltimore, Md. : 1950)|August 21, 2008
Human invariant NKT cells display alloreactivity instructed by invariant TCR-CD1d interaction and killer Ig receptorsScott Patterson, Aristeidis Chaidos, David C A Neville, et al.
Vaccine|December 18, 2017
Serotype-specific immune responses to pneumococcal conjugate vaccine among children are significantly correlated by individual: Analysis of randomized controlled trial dataMarc Lipsitch, Lucy M Li, Scott Patterson, et al.
Proceedings of the National Academy of Sciences of the United States of America|June 21, 2006
Phosphoproteomic analysis of Her2/neu signaling and inhibitionRon Bose, Henrik Molina, A Scott Patterson, et al.
Vaccine|July 17, 2016
Modeling pneumococcal nasopharyngeal acquisition as a function of anticapsular serum antibody concentrations after pneumococcal conjugate vaccine administrationRon Dagan, Christine Juergens, James Trammel, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|June 28, 2013
Comparative immunogenicity and efficacy of 13-valent and 7-valent pneumococcal conjugate vaccines in reducing nasopharyngeal colonization: a randomized double-blind trialRon Dagan, Scott Patterson, Christine Juergens, et al.
Vaccine|January 15, 2017
PCV13-vaccinated children still carrying PCV13 additional serotypes show similar carriage density to a control group of PCV7-vaccinated childrenRon Dagan, Christine Juergens, James Trammel, et al.
Human Vaccines & Immunotherapeutics|March 16, 2018
Late onset of injection site reactions after vaccination with the 13-valent pneumococcal conjugate vaccine in adult study populationsChristine Juergens, James Trammel, Yasuko Shoji, et al.
Clinical and Vaccine Immunology : CVI|July 4, 2014
Post hoc analysis of a randomized double-blind trial of the correlation of functional and binding antibody responses elicited by 13-valent and 7-valent pneumococcal conjugate vaccines and association with nasopharyngeal colonizationChristine Juergens, Scott Patterson, James Trammel, et al.
Journal of Immunology (Baltimore, Md. : 1950)|October 8, 2005
Human invariant NKT cells are required for effective in vitro alloresponsesScott Patterson, Ioannis Kotsianidis, Antonio Almeida, et al.
Pageof 7